The NIDDK Hematology Centers Program is providing a novel support mechanism for researchers to pursue new directions in non-malignant hematology. Applicants must be from any registered, domestic (U.S.), eligible organization, but those from institutions not currently part of the NIDDK Hematology Centers Program will be prioritized. Applications from investigators coming from other fields, bringing new perspectives or tools to address questions in nonmalignant hematology, are also encouraged.

P&F Type A:  $5,000 - $12,000 worth of core credits to provide equal access to services and expertise offered by any core. Rolling deadlines, abbreviated application forms, and streamlined review by Core Directors all contribute to a rapid and equitable distribution of core credits. Type A support is ideally suited for trainees who want to master a new expertise or acquire a new skill to enhance their competitiveness.  Applications for Type A projects will be accepted on a rolling basis and reviewed three times a year, starting in February 2021.

Instructions Specific to P&F Type A:  New applications should be uploaded as a single PDF file (11-point Arial font size and 0.5” margins) that must include:

• Page 1. Title, PI; Abstract (made public if awarded).
• Page 2.  Description, Significance, Figures and Literature Cited,
• Page 3.  Core use, Budget, and Justification, (for trainees, signed by lab PI), 1 page
• NIH-style Biosketch for applicant only.
• Type A projects do not require Institutional sign off by the applicant’s grant and contract office, unless required by the applicant institution’s policies.
• Applicants must obtain signed approval for costs and feasibility from the directors of the cores they wish to access.
• Project periods are limited to 12 months, and a progress report must be submitted within 120 days of the budget end date.

P&F Type B: $75,000 total award (grant) including F&A.  Use of CCEH Core resources is not required but encouraged. 

The primary goal of Type B P&F grants is to support innovative pilot research projects in non-malignant hematology, including the generation of preliminary data for larger research grants. Pilots should involve new scientific directions or the development or application of a novel technology. It is not expected that any preliminary data be provided, but the scientific premise should be supported by literature. Applications are due February 15, 2022 (5pm MST). 

Type B grants will be reviewed by a panel of approximately 10 reviewers, each reading all applications.  Reviewers will provide scores for key review criteria (significance, innovation, approach, feasibility, as well as for new direction/technology and fostering a new collaboration) then rank all applications. Reviewers will briefly describe what drove their ranking. Applications will undergo a second level of review involving the NIDDK and the HCCC. Unsuccessful applicants will be encouraged to discuss the critiques with the scientific contact below.  

This program is intended to support pilots that are not appropriate for other grant mechanisms. While applicants of any career stage are eligible, applicants will be required to describe why the project is not appropriate for other grant mechanisms (NIDDK fellowship, career development award, or research project (R) grants). Moreover, trainees and fellows will be required to describe how the pilot will support a subsequent grant application and lead to future independence (e.g., how the research direction will differentiate them from their mentor). 

Please note: Proposed research that falls outside the NIDDK/Hematology mission will be considered nonresponsive and will not be reviewed. The following link describes the NIDDK hematology mission.  NIDDK Hematology Program Directors are available to discuss the mission as well as relevant funding opportunities: 

https://www.niddk.nih.gov/research-funding/research-programs#hematologic-disease

Applications that scientifically overlap with a NIH application that is currently under review will not be reviewed. Questions about these policies should be directed to the scientific contact below.

Instructions Specific to Type B:  New applications should be uploaded as a single PDF file (11-point Arial font size and 0.5” margins). Resubmissions are not permitted; revised applications must be submitted as New. Only complete applications received by the due date will be reviewed.

• Use the PHS 398 form including face, abstract (to be made public upon award), detailed budget, biographical and other support pages, and research plan.

Research plan is limited to 4 pages and should include:

• Snapshot (1 page)
• Under separate headers answer the following questions:
• Elevator Pitch: How is the proposed pilot research a new direction in non-malignant hematology? Reference any current or pending Other Support from the PI, collaborators, or mentors, and describe how the pilot is not incremental.
• Appropriateness of mechanism: How is the proposed research a fit for the Type B P&F grant, AND not a fit for another NIDDK grant mechanism? Investigators eligible for NIDDK fellowships or career development awards are strongly encouraged to apply for those mechanisms. Investigators with substantial preliminary data are strongly encouraged to apply for a research project grant (e.g., R01).
• Pathway to independence (for applicants without independent faculty positions): How will the proposed pilot research help differentiate the trainee/fellow from their mentor(s)?   
• Specific Aims, Background and Significance (address all review criteria detailed above, 1 page)
• Research Design and Methods (2 pages)

Pages not counted, but to be included are:

• Literature Cited
• Vertebrate Animals and/or Protection of Human Subjects Approval (if applicable)
• Sharing Plan
• Budget -costs (8% F&A, PHS 398 FP4 and FP5), justification. Note: Budgets are limited to $75,000 total costs (inclusive of all F&A costs) and will be administered as a subaward to an active NIDDK Hematology Centers grant. If in-kind services from a CCEH are proposed, the total costs for the award should be reduced by the negotiated costs of the in-kind services.
• For any application proposing to use CCEH Cores, applicants must obtain signed approval for costs and feasibility from the directors of the cores they wish to access and include on Budget justification page ( CCEH Cores can be found here).
• Project periods are limited to 12 months, and a progress report must be submitted within 120 days of the budget end date.

Please upload a single PDF of your application using the “Submit Application Here”, at the end of the Funding Opportunities section (below).

For questions about application submission and receipt, please contact John Phillips: john.phillips@hsc.utah.edu.

For scientific questions, please contact Shilpa Hattangadi: hattangadism@nih.gov.

ADDITIONAL REQUIREMENTS

If an award is made, the submitted Abstract will be made public on the cceh.io website, along with the Project Title, PI Name(s), Institution, and award type.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number U24DK126127. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Awardees are also encouraged to refer to the “NIDDK Cooperative Centers of Excellence in Hematology Pilot &Feasibility Award” on their Biosketch and Other Support documents.

Awardees are expected to submit a final progress report within 120 days of the budget end date. The U24-funded HCCC may include this report, in part or in full, with its Annual Research Performance Progress Report (RPPR) to the NIH.

The HCCC may contact the PI of awards to review long-term outcomes. Awardees will be invited to present results at the annual NIDDK Hematology Centers Program Steering Committee meeting.

If not used in publications or grant submissions, data should be represented in Synapse or another relevant data repository as negative results.

DIRECTIONS TO START THE APPLICATION PROCESS for Type A or Type B  P&F  Proposals

1.  Check guidelines for eligibility
                a. Priority will be given to Junior Investigators and Postdocs.
                b. Established Investigators starting a new line of Research in nonmalignant hematology - cannot be focused on currently funded project.

2.  Determine the type of grant you wish to apply for.
                a. Type A  - Core Usage Funds Only (C-UFO) up to $12,000 (no F&A, funds made available only at Core proposed).
                b. Type B - New Pilot Proposal (HCCC-P&F) up to $75,000 including recommended F&A (Use PHS 398 forms as detailed).

3.  Contact the core director(s) of the core you will be using to initiate guidance on feasibility and costs associated with core use.

4.  Write and submit proposals as a single PDF using the detailed guidelines on length and inclusions on the FUNDING link cceh.io/funding ("red" Submit box) prior to final due date and time.
                No applications will be accepted after 5pm MST on the due date.

To read the abstracts for these projects, please click here.

To review projects funded during 2017-2020, please click here.
 

Get to know the investigators behind our current P&F projects. Click on an investigator's name to visit their website.